|I doubt they buried it. Lanza is now||elllk||01/14/22 12:17 PM|
|Agreed. Just wanted their parents, most likely, to||biosectinvestor||12/03/21 12:25 PM|
|So sad.||BearGator56||11/30/21 11:13 AM|
|Looks like they buried the technology||joeycav11||11/27/21 10:00 PM|
|Anyone know whatever happened to the trials on||BearGator56||06/21/20 10:47 PM|
|Yeah Neos has done well and I expect||elysse1kittycat||11/13/17 3:21 PM|
|Looks like your NEOS was a much better||diannedawn||11/13/17 2:40 PM|
|Immunologic Cell Teeter-Totter*||Hank615||10/27/17 2:01 PM|
|Hank615||10/27/17 2:00 PM|
|Just curious-what is the update for this company||elysse1kittycat||10/12/17 9:10 AM|
|Thanks for the update.||elysse1kittycat||07/09/17 9:54 AM|
|Amazed this board is still showing activity.||Spideyboy||07/01/17 7:48 PM|
|Ocata Therapeutics was acquired by Astellas Pharma Inc.||Renee||05/25/17 8:53 PM|
|I have a nine position in neos and||elysse1kittycat||03/14/17 9:15 PM|
|It was acquired by ALPMY a while back||lgoodman||02/27/17 5:13 PM|
|First message after years in the wilderness. What||2020||02/27/17 4:37 PM|
|Looking for an excellent pharmaceutical with three successful||sharpei||01/28/17 9:25 PM|
|Its nice to hear from you folks and||elysse1kittycat||10/07/16 12:37 AM|
|I have seen that one but don't know||fulleroots||10/04/16 8:41 PM|
|XXII?||north40000||10/03/16 2:03 AM|
|Yes brother still around . In on the||fulleroots||10/02/16 10:12 AM|
|I check in from time to time, to||All-Bidness||09/02/16 1:00 AM|
|Elysse, I invested all of the proceeds into ALPMY||lgoodman||08/23/16 12:50 PM|
|Anyone still around?||elysse1kittycat||08/23/16 10:43 AM|
|SHAME on the PHARMACEUTICAL Companies!!||Goodbuddy4863||05/09/16 6:36 PM|
|Too early to expect miracle happenings from Astellas/Ocata||north40000||03/18/16 8:37 AM|
|What is going on with Astellas. I would||smokey||03/17/16 5:26 PM|
|I was excited to reinvest in OCAT or||mvecho||03/16/16 4:39 PM|
|I appreciate that, I am starting my research||mvecho||03/16/16 4:25 PM|
|Mvecho-I suggest you do a search on Ocata-to||elysse1kittycat||03/16/16 4:19 PM|
|Hey Elysee, i have been invested in ACTC/OCAT||mvecho||03/16/16 4:16 PM|
|Booski-I agree with you about the disappointing return||elysse1kittycat||03/16/16 8:37 AM|
|I have to agree with you although in||Booski||03/16/16 7:09 AM|
|I sure hope that anyone reading this post||elysse1kittycat||03/11/16 4:54 PM|
|So ALPMY does seem to be the right||pbear||03/09/16 1:07 PM|
|I have never tried this idea: Find the||north40000||03/09/16 12:53 AM|
|Not much conversation on that one||smokey||03/08/16 9:58 PM|
|Try placing ALPMY in the IHUB search box||north40000||03/08/16 8:25 PM|
|IHUB search box and see what turns up||north40000||03/08/16 8:04 PM|
|Type in the U.S. Stock symbol in the I||north40000||03/08/16 8:02 PM|
|What do you mean NO||smokey||03/08/16 5:20 PM|
|no||Lexxy||03/08/16 5:03 PM|
|Can someone PM me about an active board||smokey||03/06/16 2:21 PM|
|It's actually pretty funny how spot on and||kyrie717||02/26/16 8:49 AM|
|Is the company using a 3D printer to||IPO$||02/25/16 3:31 PM|
|All I know is that I just returned||elysse1kittycat||02/25/16 1:05 PM|
|ALPMY closed @ $14.10.||north40000||02/24/16 9:06 PM|
|Put both symbols in a watch list, or||north40000||02/24/16 7:16 PM|
|Has anyone looked at the ticker ALPMF? The||joecarry||02/24/16 6:30 PM|
|Lanza is ACTC and Ocata so no big||pbear||02/23/16 6:27 PM|
formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics
Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333
Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.
The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts.
The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.
We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.
See our Pipeline of Ophthalmology Therapies »
Other Regenerative Medicine Programs
In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.
Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.
We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.
Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.
Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Rules of the board according to IHUB: